OTCMKTS:HEMA HemaCare (HEMA) Stock Price, News & Analysis → why 99.94% won’t make you money (From Prosper Trading Academy) (Ad) Free HEMA Stock Alerts $25.31 +0.15 (+0.60%) (As of 01/3/2020) Add Compare Share Share Today's Range$25.31▼$25.3150-Day Range$25.31▼$25.3152-Week Range$8.62▼$26.23Volume5,400 shsAverage Volume39,950 shsMarket Capitalization$346.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get HemaCare alerts: Email Address Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About HemaCare Stock (OTCMKTS:HEMA)HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.Read More HEMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEMA Stock News HeadlinesFebruary 21, 2024 | msn.comDonors flock to blood centers following Union Station shootingOctober 22, 2023 | investing.comHEMA Historical DataJune 18, 2024 | Behind the Markets (Ad)Protect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.July 6, 2023 | finanznachrichten.dePrimary Cells Market worth $2.8 billion | MarketsandMarketsJune 22, 2023 | marketwatch.comThe worldwide Therapeutic Plasma Exchange industry is currently experiencing significant growth and expanding at a 13.6% CAGR from 2023 - 2030May 16, 2023 | marketwatch.comRegion-Wise Apheresis Machines Market Analysis Forecast 2023-2030May 14, 2023 | marketwatch.com2023 Apheresis Machines Market Price & News with Size Forecast 2030May 14, 2023 | marketwatch.comPeripheral Blood Market upto 2030June 18, 2024 | Behind the Markets (Ad)Protect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.May 9, 2023 | marketwatch.com2023 Bone Marrow Transplant Market: Trends and Forecast 2031 | A Detailed Sales Channel Analysis ReportMay 4, 2023 | marketwatch.comResearch Use Human Cells Market 2023 Size, Status and Global Outlook -Charles River, Lonza, Thermo Fisher Scientific, Sigma-AldrichMay 3, 2023 | marketwatch.comApheresis Equipment Market Size 2023, Industry Share, Growth, Trends, Revenue Analysis 2023-2030May 3, 2023 | marketwatch.comBone Marrow Transplant Market Growth Opportunities and Emerging Trends till 2031April 28, 2023 | marketwatch.comApheresis Devices Market Complete Overview till 2031April 15, 2023 | marketwatch.comGlobal Continuous Flow Apheresis Device Market Growth, Size and Manufacturers Analysis Research Report and Forecast 2023-2030 By VMReportsApril 13, 2023 | marketwatch.comPeripheral Blood Market Forecasted from 2023-2030April 10, 2023 | marketwatch.comNavigating the Pharmaceutical Sterility Testing Market Growth Outlook by market Trends and market size Using a 6.9% CAGR from 2023 - 2030April 6, 2023 | marketwatch.comLeukapheresis Market | Extensive Growth by 2031April 4, 2023 | marketwatch.comBone Marrow Transplant Market 2023 Size and Forecast to 2031March 28, 2023 | marketwatch.comApheresis Machines Market Growth and Forecast till 2030March 24, 2023 | marketwatch.comTherapeutic Plasma Exchange Market Size By 2031March 23, 2023 | marketwatch.comApheresis Devices Market Growth and Forecast till 2028March 23, 2023 | marketwatch.com2023-2029 Immunohematology Testing Market Size and Market Dynamic Analysis | Latest Report by Absolute ReportsMarch 19, 2023 | marketwatch.comGlobal Therapeutic Plasma Exchange Market Insights, Emerging Trends and Latest Opportunities 2023 – 2030 By VMReportsMarch 15, 2023 | marketwatch.comIntermittent Flow Apheresis Devices Market Size 2023 Research Report by Raw Materials Analysis and Forecast till 2027March 8, 2023 | marketwatch.comPeripheral Blood Market Application, Product, Sales and Forecast 2023-2028March 7, 2023 | marketwatch.comLeukapheresis Market Application, Product, Sales and Forecast 2023-2028See More Headlines Receive HEMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HemaCare and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolOTCMKTS:HEMA CUSIP423498104 CIK801748 Webwww.hemagen.com Phone818-226-1968FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares13,691,000Free FloatN/AMarket Cap$346.52 million OptionableNot Optionable Beta1.47 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Peter C. van der Wal (Age 62)Pres, CEO & Director Ms. Rochelle J. Martel M.B.A.CPA, Chief Financial OfficerMs. Maria Pia MunizSr. VP of OperationsMr. Lou JulianoSr. VP of Global Sales & Bus. Devel.Dr. Dominic ClarkeGlobal Head of Cell TherapyKey CompetitorsPacific Health Care OrganizationOTCMKTS:PFHODCurative BiotechnologyOTCMKTS:CTYXBioRestorative TherapiesOTCMKTS:BRTXQXencorNASDAQ:XNCRANI PharmaceuticalsNASDAQ:ANIPView All Competitors HEMA Stock Analysis - Frequently Asked Questions How have HEMA shares performed in 2024? HemaCare's stock was trading at $25.31 at the beginning of 2024. Since then, HEMA stock has increased by 0.0% and is now trading at $25.31. View the best growth stocks for 2024 here. What other stocks do shareholders of HemaCare own? Based on aggregate information from My MarketBeat watchlists, some companies that other HemaCare investors own include First Majestic Silver (AG), Warner Bros. Discovery (DISCA), Cognizant Technology Solutions (CTSH), Canadian Solar (CSIQ), CMC Materials (CCMP), Athenex (ATNX), Apollo Commercial Real Estate Finance (ARI), Artisan Partners Asset Management (APAM) and Ambarella (AMBA). How do I buy shares of HemaCare? Shares of HEMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HEMA) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HemaCare Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share HemaCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.